Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0)

This study has been terminated.
Sponsor:
Collaborator:
The Hong Kong Nasopharyngeal Cancer Study Group
Information provided by:
Hospital Authority, Hong Kong
ClinicalTrials.gov Identifier:
NCT00563862
First received: November 21, 2007
Last updated: June 14, 2011
Last verified: June 2011
  Purpose

To test the therapeutic ratio of accelerated radiotherapy and/or chemotherapy on locally advanced nasopharyngeal carcinoma.


Condition Intervention
Nasopharyngeal Neoplasms
Carcinoma, Squamous Cell
Procedure: Conventional RT
Procedure: Accelerated RT
Drug: Cisplatin
Drug: 5-fluorouracil

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Prospective Randomized Study on Therapeutic Gain Achieved By Chemoradiation And/Or Accelerated Radiation For T3-4N0-1M0 Nasopharyngeal Carcinoma

Resource links provided by NLM:


Further study details as provided by Hospital Authority, Hong Kong:

Primary Outcome Measures:
  • Failure free survival rate [ Time Frame: 5-year ]

Secondary Outcome Measures:
  • Overall survival rate [ Time Frame: 5-year ]
  • Disease-specific survival rate [ Time Frame: 5-year ]
  • Complication-free rates [ Time Frame: 5-year ]

Enrollment: 465
Study Start Date: July 1999
Study Completion Date: June 2007
  Eligibility

Ages Eligible for Study:   up to 70 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Undifferentiated or non-keratinizing carcinoma
  • Tumor staged as T3-4 AND N0-1
  • No evidence of distant metastasis (M0)
  • Performance status: 0-2
  • Marrow: WBC >= 4 and platelet = 100
  • Renal: creatinine clearance = 60
  • Informed consent

Exclusion Criteria:

  • WHO type I squamous cell carcinoma or adenocarcinoma
  • Age >= 70
  • Palliative intent or tumor extent mandating AP opposing facio-cervical fields
  • Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years
  • Previous radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume
  • Previous chemotherapy
  • Patient is pregnant or lactating
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00563862

Locations
China
Pamela Youde Nethersole Eastern Hospital
Hong Kong, China
Prince of Wales Hospital
Hong Kong, China
Queen Elizabeth Hospital
Hong Kong, China
Queen Mary Hospital
Hong Kong, China
Tuen Mun Hospital
Hong Kong, China
Sponsors and Collaborators
Hospital Authority, Hong Kong
The Hong Kong Nasopharyngeal Cancer Study Group
Investigators
Principal Investigator: Anne WM Lee, Dr Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00563862     History of Changes
Other Study ID Numbers: L/M-78 to PYH 08/79, HARECCTR0500024, NPC99-02
Study First Received: November 21, 2007
Last Updated: June 14, 2011
Health Authority: Hong Kong: Ethics Committee

Keywords provided by Hospital Authority, Hong Kong:
Nasopharyngeal Carcinoma
T3-4N0-1M0

Additional relevant MeSH terms:
Nasopharyngeal Neoplasms
Head and Neck Neoplasms
Nasopharyngeal Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Otorhinolaryngologic Neoplasms
Pharyngeal Neoplasms
Carcinoma
Carcinoma, Squamous Cell
Otorhinolaryngologic Diseases
Pharyngeal Diseases
Stomatognathic Diseases
Fluorouracil
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014